Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

Autoři	STAESSEN Jan THIJS Lutgarde STOLARZ-SKRZYPEK Katarzyna BACCHIERI A. BARTON John ESPOSITI Ezio LEEUW Peter DŁUŻNIEWSKI Mirosław GLORIOSO Nicola JANUSZEWICZ Andrzej MANUNTA Paolo MILYAGIN Viktor NIKITIN Yuri SOUČEK Miroslav LANZANI Chiara CITTERIO Lorena TIMIO Mario TYKARSKI Andrzej FERRARI P. VALENTINI G. KAWECKA-JASZCZ K. BIANCHI G.
Rok publikování	2011
Druh	Článek v odborném periodiku
Časopis / Zdroj	Trials
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1186/1745-6215-12-13
Obor	Kardiovaskulární nemoci včetně kardiochirurgie
Klíčová slova	Hypertension; sodium; cardiovascular disease
Popis	The Ouabain and Adducin for Specific Intervention on Sodium in Hypertension (OASIS-HT) Trial was a phase-2 dose-finding study of rostafuroxin, a digitoxygenin derivative, which selectively antagonizes the effects of endogenous ouabain (EO) on Na+,K+-ATPase and mutated adducin. Rostafuroxin lowered blood pressure (BP) in some animal models and in humans.